Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05052671 · ClinicalTrials.gov registry record

ctDNA Assay in Patients With Resectable Pancreatic Cancer

A clinical trial of Pancreas Cancer, sponsored by University of Oklahoma.

Recruiting
Registry status
50
Enrollment target
2
Study locations

NCT05052671 is a study of Pancreas Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 50 participants, below the 906-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05052671, a study of Pancreas Cancer, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
50 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.

Conditions Studied

Pancreas Cancer

Study Locations (2)

Oklahoma

  • University of Oklahoma - Oklahoma City
  • Stephenson Cancer Center- Tulsa - Tulsa

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-05-25
Est. Completion 2028-12

Sponsor

University of Oklahoma

358 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05052671

The ClinicalTrials.gov registry entry for NCT05052671 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 906-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT05052671 reports 2 study locations spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT05052671 about?

NCT05052671 is a clinical study titled "ctDNA Assay in Patients With Resectable Pancreatic Cancer". The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may pr...

What is the current status of trial NCT05052671?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-05-25. Estimated completion is 2028-12.

What conditions does trial NCT05052671 study?

This clinical trial studies the following conditions: Pancreas Cancer.

Who is sponsoring clinical trial NCT05052671?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05052671 being conducted?

This trial has 2 study locations across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreas Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreas Cancer

All registered trials for this condition

Oklahoma

All trials with a study site in Oklahoma

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.